KalVista Pharmaceuticals
Generated by Meeveem AI
"Advancing oral therapies to transform care for people living with rare diseases."
Framingham, MA
•251 - 500 Employees
•Pharmaceuticals
About KalVista Pharmaceuticals
KalVista Pharmaceuticals develops oral medicines for people living with rare diseases, beginning with hereditary angioedema (HAE), a genetic condition causing unpredictable attacks of tissue swelling. The company's first product, approved by the FDA, is the only oral on-demand treatment for HAE, offering an alternative to injectable therapies that have long defined the treatment landscape. With over 250 employees worldwide, KalVista combines deep scientific expertise in the kallikrein-kinin system with proven drug discovery capabilities. The pipeline includes oral Factor XIIa inhibitors for HAE prophylaxis and treatments for thrombosis and inflammation, empowering patients to manage their conditions with greater convenience.
275
Team Members
2011
Founded
Pharmaceuticals
Sector
Hybrid
Work Environment
Our Vision
A world where people with rare diseases can manage their conditions with simple, effective oral therapies, free from the burden of injections and restrictive treatment regimens, living full and empowered everyday lives.
Our Mission
At KalVista, our mission is to develop and deliver life changing oral therapies that meaningfully improve the lives of people affected by rare diseases with significant unmet needs.